The invention concerns adult multipotent human stem cells, characterized in that they have: i) significant telomerase activity, ii) an HLA Class I negative phenotype, iii) a normal karyotype, iv) a capacity to become quiescent, v) a capacity for self-renewal preserved for at least 130 population doublings.